Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Amerikaanse aandelen  /  Hemispherx BioPharma, Inc (Public, AMEX:HEB)

Ontvang nu dagelijks onze kooptips!

word abonnee

Amerikaanse aandelen« Terug naar discussie overzicht

Hemispherx BioPharma, Inc (Public, AMEX:HEB)

13.337 Posts
Pagina: «« 1 ... 662 663 664 665 666 667 »» | Laatste | Omlaag ↓
  1. [verwijderd] 26 maart 2012 15:54
    quote:

    bertje007 schreef op 30 januari 2012 23:16:

    We hebben de 0.50 aangetikt maar zijn er helaas niet doorgegaan, hopelijk morgen meer geluk.

    Tijd voor nog enkele persberichtjes.
    Hemispherx BioPharma, Inc. Comm (HEB)
    -AMEX

    0.4002 Up 0.0314(+8.51%)

    Hemispherx Publishes Peer-Reviewed Data on an Analysis of the Incidence and Clinical Impact of Neutralizing Antibodies (NABs) Against Recombinant Interferons Versus Natural Human Interferons (IFNs)

    finance.yahoo.com/news/hemispherx-pub...

    Skip
  6. [verwijderd] 14 augustus 2012 23:25
    Hemispherx BioPharma, Inc (NYSEAMEX:HEB) shares climbed 9.12% to $0.480 in the early hour after the company announced that it filed on July 31, 2012 with the U.S. Food and Drug Administration complete response to the FDA's November 25, 2009 Complete Response Letter in support of Ampligen's New Drug Application for Chronic Fatigue Syndrome (CFS). On August 10, 2012, the FDA acknowledged in writing receipt of the Company's August 1, 2012, response stating, "It considers this a complete, class 2 response to November 25, 2009, action letter. Therefore, the user fee goal date is February 2, 2013.

    He Bert, blijven zitten, wordt het leuk.. Of eruit.. heb de neiging om lekker te blijven zitten ..maybe a spike..

  7. p/o 15 augustus 2012 17:49
    Sta om te verkopen aan 0.56, nadat we gisteren boven de 0.51 gingen had ik al terug hoop, maar na de 0.43 van daarstraks zal ik terug wat langer mogen wachten.

    Ik vermoed dat ze van de stijgingen gebruik maken om vers geld op te halen. (waardoor we dan telkens terug die dalingen van 15 - 20% krijgen.
  15. p/o 24 augustus 2012 17:48
    En toch vertrouw ik het ook niet. (en ik zeg dit als aandeelhouder)

    Ze willen nog altijd geld op halen door massaal aandelen ter beschikking te stellen.

    On July 23, 2012, Hemispherx Biopharma, Inc. (the “Company”) entered into an Equity Distribution Agreement with Maxim Group
    LLC (the “Agreement”) to create an at-the-market equity program under which it may sell up to $75,000,000 worth of shares of its common
    stock (the “Shares”) from time to time through Maxim Group LLC, as sales agent (the “Agent”). Under the Agreement, the Agent will be
    entitled to a commission at a fixed commission rate of 4.0% of the gross sales price of Shares sold under the Agreement, up to aggregate gross
    proceeds of $10,000,000, and, thereafter, at a fixed commission rate of 3.0% of the gross sales price of Shares sold under the Agreement.
  18. johnny baboa 28 augustus 2012 19:14

    DEZE BEDOEL IK

    Bandito1983 schreef op 14 dec 2010 om 15:30:

    [...]

    November 2010 - If you purchased or otherwise acquired Hemispherx Biopharma, Inc. (“Hemispherx”) common stock from February 18, 2009 through and including December 1, 2009, then you could receive a payment from the proposed Settlement of a securities class action lawsuit pending in Court.

    A Settlement has been proposed that will provide a settlement fund of $3.6 million in cash, plus interest (the “Settlement Fund”), to settle claims of investors who suffered damages from buying or otherwise acquiring Hemispherx common stock from February 18, 2009 through and including December 1, 2009. A hearing will be held on January 20, 2011 in Philadelphia, PA, to determine (1) whether the proposed Settlement (the "Settlement") of the above-captioned action ("Action") for $3,600,000 should be approved by the Court as fair, reasonable, and adequate; (2) whether the motion of Co-Lead Counsel for an award of attorneys' fees and reimbursement of expenses should be approved; and (3) whether the Action should be dismissed with prejudice.

    November 2009 - An investor in Hemispherx BioPharma, Inc (Public, AMEX:HEB) has filed a lawsuit in the United States District Court for the Eastern District of Pennsylvania on behalf of those who purchased the securities of Hemispherx Biopharma, Inc. (AMEX: HEB) between February 18, 2009 and October 30, 2009, over alleged violations of Federal Securities Laws.

    According to the complaint the plaintiff alleges that the defendants violated the federal securities laws by misleading investors regarding the status of Hemispherx's New Drug Application ("NDA") for its drug Ampligen with the U.S. Food and Drug Administration ("FDA"). Specifically, so the lawsuit, defendants failed to disclose that the FDA had requested several reports from Hemispherx Biopharma before the NDA could even be considered, thus delaying the possible approval of Ampligen by several months at a minimum. Then, on November 2, 2009, when Hemispherx Biopharma disclosed this information, the price of Hemispherx Biopharma securities (HEB) fell 20% to close at $1.13 on the next trading day, November 3, 2009.

    Hemispherx BioPharma, Inc said in a press release that it believes that the lawsuit is without merit and the fraud claim is irrefutably false.

    Hemispherx Biopharma, Inc., located inPhiladelphia, PA, is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s products include Ampligen and Alferon N and Injection. Hemispherx BioPharma, Inc reported in 2007 Total Revenue of $1.06million and in 2008 Total Revenue of $0.27million. Shares of Hemispherx BioPharma, Inc traded recently at $1.08 per share

    shareholdersfoundation.com/case/hemis...

    Deze bedoel ik , ik heb een cheque gekregen van 528.56 dollar [5000
    aandelen toen in mijn bezit]

13.337 Posts
Pagina: «« 1 ... 662 663 664 665 666 667 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 911,51 -0,38%
EUR/USD 1,0856 -0,02%
FTSE 100 8.416,45 -0,09%
Germany40^ 18.723,70 -0,24%
Gold spot 2.421,50 -0,19%
NY-Nasdaq Composite 16.794,87 +0,65%

Stijgers

Flow T...
+3,27%
SBM Of...
+2,38%
OCI
+2,13%
INPOST
+1,82%
Euroco...
+1,56%

Dalers

Alfen ...
-15,53%
Sif Ho...
-6,63%
AMG Cr...
-5,70%
Avantium
-4,78%
EBUSCO...
-4,44%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!